ISB News

The inaugural ISB Virtual Microbiome Series highlighted recent in silico, in vitro, and in vivo advances toward engineering the gut microbiome to resolve complex diseases.

ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.

Everybody pees and poops. What if there was a way to use the byproducts of our everyday bodily functions to understand the general health of a population? That is exactly what MIT’s Dr. Eric Alm is pursuing. In an ISB-Town Hall Seattle live stream, Alm discussed the promise of this novel form of public health tracking. 

By analyzing blood plasma samples taken at several time points, ISB researchers have identified specific proteins that persistently presented as outliers and signaled metastatic cancer well before patients were diagnosed. The findings were published in the journal Scientific Reports.

Diseases develop gradually over years, sometimes decades, before symptoms appear, and are due to malfunctioning physiological processes brought about by our genes and environment. In research published in the journal Proceedings of the National Academy of Sciences (PNAS), ISB researchers have shown how an individual’s genetic risk for disease is often reflected in their blood.

There is a dichotomy between Bacteroides- and Prevotella-dominated guts — two common gut bacterial genera — and there is a significant barrier when it comes to transitioning from one to the other.